Annual Event Webinar #6: Front Line Ovarian Cancer: Turning up the Heat on Immunotherapy

All times listed are Central Daylight Time (CDT).

Moderators/Distillants: Leslie M. Randall, MD, and Dan S. Veljovich, MD

• Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial – J. Ledermann
• Randomized double-blind placebo controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients – R. Rocconi
• Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab – M. Hardesty
• A pilot study of nivolumab in combination with front-line neoadjuvant dose-dense paclitaxel and carboplatin chemotherapy in patients with high-grade serous ovarian cancer – C. F. Friedman

Moderators to synthesize these 4 abstracts with input from the authors:

• Heated intraperitoneal chemotherapy (HIPEC) use for ovarian cancer in the United States increases after publication of clinical trial and is associated with higher short-term cost and morbidity
• Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy with paclitaxel and cisplatin versus cisplatin alone at interval debulking surgery in women with epithelial ovarian cancer
• Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy (HIPEC) at time of minimally invasive interval debulking surgery versus laparotomy
• Hyperthermic intraperitoneal chemotherapy at the time of minimally invasive interval debulking surgery

Download Abstract (PDF)

ACCESS FULL SERIES (NON-CE) | CE ONDEMAND WEBINAR

Learning Objectives

1. Describe the results from the first phase 3 trial of a checkpoint inhibitor (avelumab; anti–PD-L1) in patients with previously untreated epithelial ovarian cancer.
2. Identify opportunities of dual targeted vaccines for ovarian cancer maintenance stratified by BRCA status
3. Summarize the efficacy and safety of niraparib + bevacizumab combination therapy in patients with ovarian cancer after response to front-line platinum-based chemotherapy.
4. Describe the toxicities and the effect on the tumor microenvironment of adding nivolumab to upfront carboplatin and paclitaxel
5. Describe trends in use of heated intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment after publication of van Driel et al’s “HIPEC in Ovarian Cancer” was published in January 2018. Compare associated rates of hospital-based outcomes, including length of stay, intensive care unit admission, complications, and costs, in ovarian cancer patients who underwent surgery with or without HIPEC.
6. Describe the comparative outcomes of type of chemotherapy regimen used at time of HIPEC.
7. Summarize perioperative outcomes in women with advanced epithelial ovarian cancer (EOC) undergoing interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) via minimally invasive interval debulking surgery (MIIDS) or laparotomy (LAP).
8. Demonstrate insertion of HIPEC probes via minimally invasive surgical incision.

Joint Accreditation

In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

AMA Credit Designation Statement – Physicians

The Society of Gynecology Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

ANCC Credit Designation Statement – Nurses

This activity has been approved for a maximum of 1.0 nursing contact hours.

ACPE Credit Designation Statement – Pharmacists

Each activity has been approved for a maximum of 1.0 contact hours of pharmacy continuing education credit. UAN number JA00007238-0000-20-010-L01-P.

PAs may claim a maximum of 1.0 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society.